ALLEGATO B ai fini della pubblicazione

Decreto Rettore Università di Roma "La Sapienza" n 231/2021 del 26/01/2021

OMBRETTA MELAIU
Curriculum Vitae

Place: Roma
Date: 10/03/2021

Part I – General Information

Part II – Education

Type	Year	Institution	Notes (Degree, Experience,…)
University graduation	2007	University of Pisa, Pisa (Italy)	Bachelor Degree in Biological and Molecular Science; Mark: 110/110 with Honours. Title of thesis: "Adiponectina: un nuovo indicatore di rischio cardiovascolare ". Tutor: Dr. Giannessi.
University graduation	2009	University of Pisa, Pisa (Italy)	Master degree in General Physiopatological Sciences - Biology 6/S; Mark: 110/110 with Honours. Title of thesis: "Biomarcatori cardiometabolici ed infarto del miocardio: studio in un modello sperimentale animale ". Tutor: Dr. Giannessi.
Licensure 01	2010	University of Pisa, Pisa (Italy)	Qualification as Professional Biologist (Registration Number: EA_019560)
PhD	2013	University of Pisa, Pisa (Italy)	PhD: Research Doctorate School in Biological and Molecular Sciences. Title of thesis: "Identification and characterization of genes involved in the malignant pleural mesothelioma". Tutor: Prof. Landi.
Specialty	2017	University of Roma Tor Vergata, Roma (Italy)	Specialty in Clinical Pathology and Biochemistry (Specializzazione). Mark: 50/50 with Honours. Title of thesis: "Significato clinico delle cellule immunitarie infiltranti tessuti di neuroblastoma. Tutors: Prof. Sergio Bernardini/Doriana Fruci.

Part III – Appointments

IIIA – Academic Appointments

Start	End	Institution	Position
April 2013	April 2015	University of Pisa, School of Medicine and Surgery, Section of Occupational Medicin, Pisa (Italy).	Research Fellow (borsa di studio) involved in "Study of new biomarkers for the clinical surveillance of workers previously exposed to asbestos".
June 2017	May 2020	University of Pisa, Department of Biology, Genetics Unit, Pisa (Italy).	Ricercatore a tempo determinato di tipo A (RTDA, BIO/18) involved in research activity focused on the study of the tumor immune microenvironment of adult and pediatric cancers.

IIIB – Other Appointments

Start	End	Institution	Position
April 2012	December 2012	Imperial College, Oncology and Surgery Department, London (UK).	Visiting scientist involved in research project entitled "Identification and characterization of genes involved in the malignant pleural mesothelioma".
May 2015	December 2016	Bambino Gesù Children's Hospital, Oncohematology Department, Immunogenetics Unit, Rome (Italy).	Research Fellow involved in study entitled "Characterization of tumor-infiltrating T lymphocytes in therapy-resistant neuroblastoma patients".
January 2017	May 2017	Bambino Gesù Children's Hospital, Oncohematology Department, Immunogenetics Unit, Rome (Italy).	Researcher supported by Fondazione Umberto Veronesi involved in study entitled "Dissecting the immune heterogeneity of neuroblastoma microenvironment to improve patient risk stratification and therapy".
June 2017	May 2020	Bambino Gesù Children's Hospital, Oncohematology Department, Immunogenetics Unit, Rome (Italy).	University researcher affiliated with Bambino Gesù Children's Hospital (distaccato IRCCS) involved in study entitled "Dissecting the immune heterogeneity of neuroblastoma microenvironment to improve patient risk stratification and therapy".
June 2020	now	Bambino Gesù Children's Hospital, Oncohematology Department, Immunogenetics Unit, Rome (Italy).	Researcher (co.co.co) involved in study entitled "Functional immune characterization of the neuroblastoma microenvironment to develop personalized cancer immunotherapy".

Part IV – Teaching experience

Year	Institution	Lecture/Course
2011/2012	University of Pisa (Italy)	Co-tutorship of degree thesis entitled "Ruolo dei Microrna e dei loro siti target nel mesotelioma pleurico maligno" (for Master degree in Cellular and Molecular Biology). Student: Chiara De Santi.
2011/2012	University of Pisa (Italy)	Co-tutorship of degree thesis entitled "Identificazione e caratterizzazione dei geni coinvolti nel mesotelioma pleurico maligno" (for Master degree in Cellular and Molecular Biology). Student: Elisa Bracci.
2011/2012	University of Pisa (Italy)	Co-tutorship of degree thesis entitled "Mesotelioma ed RNA interference: stato dell'arte e nuove frontiere" (for Bachelor degree in Biological Science). Student: Giulio Ciucci.
2011/2012	University of Pisa (Italy)	Co-tutorship of degree thesis entitled "Identificazione della 3'UTR umana del gene NPPC (natriuretic-precursor peptide C) e dei suoi polimorfismi genetici" (for Master degree in Cellular and Molecular Biology). Student: Mariasole Facioni.
2013/2014	University of Pisa (Italy)	Co-tutorship of degree thesis entitled "Identificazione e caratterizzazione di geni implicati nel mesotelioma pleurico maligno" (for Master degree in Cellular and Molecular Biology). Student: Calogerina Catalano.
2013/2014	University of Pisa (Italy)	Co-tutorship of degree thesis entitled "Valutazione del ruolo svolto da geni sovraespressi nel mesotelioma tramite RNA interference" (for Master degree in Cellular and Molecular Biology). Student: Giovanni Giangreco.
2017/2018	University of Pisa (Italy)	Teaching assistant for the course of "Genetics" (for the Bachelor degree in Biological Sciences, 9 credits).
2017/2018	University of Pisa (Italy)	Chair holder (titolare di cattedra) of the course "Genetics and Genomics analyses" (for the Master degree in Cellular and Molecular Biology, 6 credits).
2018/2019	University of Pisa (Italy)	Teaching assistant for the course of "Genetics" (for the Bachelor degree in Biological Sciences, 9 credits).
2018/2019	University of Pisa (Italy)	Chair holder (titolare di cattedra) of the course "Genetics and Genomics analyses" (for the Master degree in Cellular and Molecular Biology, 6 credits).

2018/2019	University of Pisa (Italy)	Correlator of the degree thesis entitled "Messa a punto di un modello 3D di microbiota fecale in vitro" (for the Master degree in in Biology Applied to Biomedicine). Student: Marco Calvigioni.
2018/2019	University of Pisa (Italy)	Correlator of the degree thesis entitled "Polymeric nanoparticle-mediated Enzyme Replacement Therapy for the treatment of Krabbe disease" (for the Master degree in Molecular Biotechnology). Student: Gabriele Parlanti.
2019/2020	University of Pisa (Italy)	Teaching assistant for the course of "Genetics" (for the Bachelor degree in Biological Sciences, 9 credits).
2019/2020	University of Pisa (Italy)	Chair holder (titolare di cattedra) of the course "Genetics and Genomics analyses" (for the Master degree in Cellular and Molecular Biology, 6 credits).
2020/2021	University of Pisa (Italy)	Free assignment of teaching for the course "Genetics and Genomics analyses" (for the Master degree in Cellular and Molecular Biology, 6 credits).

Part Va - Society memberberships

Year	Title
2014	American Association for Cancer Research (AACR) member.
2014	European Association for Cancer Research (EACR) member.
2014	Member of Italian Group of Mesothelioma (GIMe) and coordinator of the GIMe newsletter.
2018	Società Italiana di Immunologia Immunologia Clinica ed Allergologia (SIICA) member.

Part Vb - Awards and Honors

Year	Title
2014	Award for Best poster presentation at The XIII Congress of the Italian Federation of Life Sciences (FISV, Pisa - Abstract entitled: Are MSLN, CFB and CCNO cancer genes of mesothelioma?).
2018	European Congress of Immunology 2018 (ECI2018) - TRAVEL GRANT to Amsterdam for Poster presentation entitled: Clinical relevance of intratumoral dendritic cells in neuroblastoma.
2020/21	Peer Review activity for Cancers (IF: 6.126), Diagnostics (IF: 2.489), and Mutagenesis (IF: 3.379).
2021	Fondazione Umberto Veronesi Award for best publication 2020.

Part Vc – Selection for Oral Presentation at national and international conferences

2011	Selected as Oral presenter at the Società Italiana di Mutagenesi Ambientale (S.I.M.A.) Conference, Parma. Oral presentation entitled: Identification and characterization of genes involved in the malignant pleural mesothelioma.
2013	Selected as Oral presenter at the Società Italiana di Mutagenesi Ambientale (S.I.M.A.) Conference, Padova. Oral presentation entitled: Comparative Genomic Hybridization Studies on Mesothelioma show a Parallel Fate of 1p21-1p22 and 9p21 Bands and a Chromosomally Stable Sub-Group.
2013	Selected as Oral presenter at the Osservatorio Nazionale Amianto (ONA) Convegno giuridico-scientifico, Pisa. Oral presentation entitled: Le ultime acquisizioni scientifiche in materia di mesotelioma.
2015	Selected as Oral presenter at the IV Workshop AIEOP in lab, Napoli. Oral presentation entitled: Ruolo dei linfociti T infiltranti il tumore come potenziali marcatori prognostici e terapeutici in pazienti affetti da forme aggressive di neuroblastoma.
2017	Selected as Oral presenter at the Giornata Romana di Immunologia, Roma. Oral presentation entitled: Dissecting the tumor immune microenvironment in neuroblastoma.
2021	Selected as Oral presenter at the Advance Neuroblastoma Research (ANR) meeting (webinars). Oral presentation entitled: Cellular and gene signatures of tumor-infiltrating dendritic cells and natural killer cells predict favorable clinical outcome of neuroblastoma.

Part Vd – Selection for Poster Presentation at national and international conferences as first author

2011	XIV Congresso Nazionale SIGU (Società Italiana di Genetica Umana) Milano. Poster title: "Identification and characterization of genes involved in the malignant pleural mesothelioma." **Melaiu O**, Cristaudo A, Bonotti A, Bruno R, Lucchi M, Foddis R, Gemignani F, Landi S.
2012	XII CONGRESSO FISV (Federazione Italiana Scienze della Vita) Roma. Poster title: "Screening of MPM patients for activating somatic mutations within PDGFR-beta". **Melaiu O**, Fontanini G, Costa B, Boldrini L, Mutti L, Sensi E, Bendinelli S, Bracci E, Lucchi M, Favoni R, Gemignani F, Landi S.
2013	Convegno AGI (Associazione Genetica Italiana) Cortona. Poster title: "Role of mesothelin and calretinin in malignant pleural mesothelioma." **Melaiu O**, Stebbing J, Lombardo Y, Bracci E, Pellegrini S, Melissari E, Uehara N, Bonotti A, Cristaudo A, Foddis R, Lucchi M, Mutti L, Barale R, Gemignani F, Giamas G, Landi S.
2014	XIII Congress of the Italian Federation of Life Sciences (FISV) Pisa. Poster title: "Are MSLN, CFB and CCNO cancer genes of mesothelioma?" **Melaiu O**, Barone E, Cipollini M, Figlioli G, Paolicchi E, Pellè L, De Santi C, Mutti L, Cristaudo A, Bonotti A, Foddis R, Gemignani G, Landi S. Best poster awarded.
2015	4th Neuroblastoma Research Symposium Newcastle, UK. Poster title: "Tumor-infiltrating T lymphocytes improve clinical outcome of therapy-resistant neuroblastoma." **Melaiu O**, Mina M, Boldrini R, Pezzullo M, Furlanello C, Castellano A, Locatelli F, Fruci D.
2018	Advances in Neuroblastoma Research (ANR2018) Meeting San Francisco Poster title: "

	Immune microenvironment in neuroblastoma: clinical and therapeutic relevance." **Melaiu O**, Chierici M, Boldrini R, Jurman G, Castellano A, Furlanello C, Locatelli F, Fruci D.
2018	5th European Congress of Immunology (European Congress of Immunology) ECI2018 Amsterdam. Poster title: "Clinical relevance of intratumoral dendritic cells in neuroblastoma". **Melaiu O**, Chierici M, Lucarini V, Compagnone M, Ziccheddu G, Jurman G, Boldrini R, Castellano A, Furlanello C, Locatelli F, Fruci D.

Part VI - Funding Information [grants as PI-principal investigator or I-investigator]

Year	Title	Program
2016	Collaborator of the project entitled "Dissecting the immune heterogeneity of neuroblastoma microenviroment to improve patient risk stratification and therapy".	A.I.R.C. (IG18495)
2017	Personal fellow for the project entitled "Dissecting the immune heterogeneity of neuroblastoma microenvironment to improve patient risk stratification and therapy".	Fondazione Umberto Veronesi
2017	Finanziamento delle Attività di Base di Ricerca (FFABR)	Agenzia nazionale di valutazione del sistema universitario e della ricerca (ANVUR)
2018	Finanziamento di Ateneo "Rating60%2018".	University of Pisa
2018	2018 Collaborator of the project entitled "Identification and characterization of deregulate genes in malignant pleural mesothelioma".	A.I.R.C. (IG2018)
2019	Finanziamento di Ateneo Rating60%2020.	University of Pisa
2020	Unit of the project entitled "Autophagy manipulation as a novel strategy for stimulating the immune response in neuroblastoma".	Ricerca Finalizzata, Ministero della salute (GR-2019-1236923)
2020	Collaborator of the project entitled Functional immune characterization of the neuroblastoma microenvironment to develop personalized cancer immunotherapy".	A.I.R.C. (IG24345)

Part VII – Research Activities

Keywords	Brief Description
Tumor microenvironment	I am interested in studies focused on translating basic research knowledge in the field of immuno-oncology into clinical applications.
Immuno-oncology Immuno-genetics Pediatric cancer Solid tumors	Specifically during these years I and colleagues elucidated the role of tumor-infiltrating immune cells in improving clinical outcomes of pediatric cancers as neuroblastoma (NB) (Melaiu et al., Clin Cancer Research 2017) and extracranial germ-cell tumors (Melaiu, Boldrini et al., OncoImmunology 2018) patients.
	In NB we demonstrated that the combination of PDL1/HLA-I is a robust marker to predict clinical outcome of this neoplasm and that MYC and MYCN regulate PD-L1 expression both in vitro and vivo, indicating that their pharmacologic inhibition could represent a novel strategy for targeting PD-L1 expression in High risk-NB patients (Melaiu et al., Clin Cancer Research 2017).
	More recently, we showed that T cells, dendritic cells (DCs) and NK cells are positively correlated in human NB, both at transcriptional and protein levels, and associated with a favorable clinical outcome of tumor patients (Melaiu et al., Nat Comm 2020). We identified gene signatures related to these cell types that were strongly correlated with the expression of PD-1 and PD-L1, thus unveiling a key prognostic role of DC and NK cells and their evaluation as promising clinical biomarkers to predict prognosis and immunotherapy efficacy in both NB patients and adult cancers as colon, breast, head and neck carcinomas and melanoma.
	In collaboration with other research groups, I contributed to (i) demonstrated the immunomodulatory role of Nutlin-3a, a nontoxic small-molecule antagonizing the inhibitory interaction of MDM2 with the tumor suppressor p53, which might be prospectively used for a novel NK cell-based immunotherapy for NB (Brandetti et al., Oncoimmunology 2017; Veneziani et al., Cancer Immunol Res. 2021), as well as to (ii) propose the modulation of CD39 as a new strategy to restore partially exhausted CD8+ TILs in colorectal, and head and neck cancers (Int J Cancer et al., 2020), and to (iii) profile the immunome in combination with the secretome of colorectal cancer microenvironment (Manuscript in preparation).
	Given the crucial importance of the immune cells as component of the tumor microenvironment (TME), I am presently involved in research projects relied on discovering and defining druggable gene targets in tumor cells and key pathways in the tumor microenvironment able to reprogram cold immune desert tumors into hot inflamed immune infiltrated tumors, in a target-personalized manner. To this aim, taking advantage of both human tissue specimens and murine models we (i) refine risk assessment in NB patients through an in-depth functional characterization of the immune landscape of the TME, (ii) identify new immuno-oncological treatment regimens for NB and other tumor types to improve recruitment of functional immune cells, thanks the generation of both murine-derived organotypic tumor sheroids (MDOTS) and patient-derived organotypic tumor sheroids (PDOTS) co-cultured with autologous T-cells, and (iii) study the molecular mechanisms conferring resistance/sensitivity to the identified immune-oncology drugs (one manuscript in preparation and other

research work in progress).
TECHNICAL SKILLS: Purification and extraction of RNA, DNA, proteins. Real Time-qPCR for gene/miRNA expression and genotyping. Automatic Sequencing. Western Blotting. ELISA. Cell cultures. Cell transfections and infections with lentiviral vectors. Molecular cloning techniques. Site-directed mutagenesis. Luciferasy assay. Apoptosis assay. Flow Cytometry. Chromatin immunoprecipitation. Manipulation of spheroids and organoids of human and murine derivation. Manipulation of mouse models. Immunohistochemistry. Multiplex Immunofluorescence. RNAscope. Nanostring assay. Exome sequencing (NGS). NGS data analysis. Proteome Profiler Mouse/Human Chemokine Array.
COMPUTER SKILLS: Good knowledge of Microsoft Office Software package; "UCSC Genome-Browser", "Blast" and "Primers design tools"; data-mining softwares: "Gene Prospector", "Coremine", "SNPs3D"; pathways analysis softwares: "Webgestalt Gene", "Onto-Express",e "DAVID Functional Annotation Bioinformatics Microarray Analysis"; microRNA binding prediction softwares: "Miranda", "Mirbase" and "Target-scan". Exome sequence data analysis: Tgex, IGV for BAM and VCF files.

Part VIII – Summary of Scientific Achievements

Product type	Number	Data Base	Start	End
Papers [international]	36	PubMed, Scopus	2010	2021

Total Impact factor	200.947
Total Citations	365
Average Citations per Product	10.14
Hirsch (H) index	11
Normalized H index*	1.37

*H index divided by the academic seniority.

Part IX– Selected Publications

List of the publications selected for the evaluation. For each publication report title, authors, reference data, journal IF (if applicable), citations, press/media release (if any).

Selected for the evaluation 20 out of 36 publications presented here in descending chronological order:

1) Dendritic Cells: Behind the Scenes of T-Cell Infiltration into the Tumor Microenvironment.
Melaiu O*, Lucarini V*, Tempora P, D'Amico S, Locatelli F, Fruci D. * = Equally contribution.
Cancers (Basel). 2021 Jan 23;13(3):433. PMID: 33498755. (IF:6.126).

2) Nutlin-3a Enhances Natural Killer Cell-Mediated Killing of Neuroblastoma by Restoring p53-Dependent Expression of Ligands for NKG2D and DNAM-1 Receptors.
Veneziani I, Infante P, Ferretti E, **Melaiu O**, Battistelli C, Lucarini V, Compagnone M, Nicoletti C, Castellano A, Petrini S, Ognibene M, Pezzolo A, Di Marcotullio L, Bei R, Moretta L, Pistoia V, Fruci D, Barnaba V, Locatelli F, Cifaldi L.

Cancer Immunol Res. 2021 Feb;9(2):170-183. PMID: 33303573 (IF:8.728).

3) Cellular and gene signatures of tumor-infiltrating dendritic cells and natural-killer cells predict prognosis of neuroblastoma.
Melaiu O, Chierici M, Lucarini V, Jurman G, Conti LA, De Vito R, Boldrini R, Cifaldi L, Castellano A, Furlanello C, Barnaba V, Locatelli F, Fruci D.
Nat Commun. 2020 Nov 25;11(1):5992. PMID: 33239635 (IF: 12.121; Citations=4).

4) Common gene variants within 3'-untranslated regions as modulators of multiple myeloma risk and survival.
Melaiu O, Macauda A, Sainz J, Calvetti D, Facioni MS, Maccari G, ..., Landi S, Campa D, Canzian F, Gemignani F.
Int J Cancer, 2020, Apr 15;148(8):1887-1894. PMID: 33152124. (IF 5.145).

5) Impact of Natural Occurring ERAP1 Single Nucleotide Polymorphisms within miRNA-Binding Sites on HCMV Infection.
Melaiu O*, D'Amico S, Tempora P, Lucarini V, Fruci D*. * = Corresponding authors.
Int J Mol Sci. 2020 Aug 15;21(16):5861. PMID: 32824160 (IF 4.556; Citation=2).

6) News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors.
Melaiu O, Lucarini V, Giovannoni R, Fruci D, Gemignani F.
Semin Cancer Biol. 2020 Jul 10:S1044-579X(20)30156-5. PMID: 32659257 (IF 11.09; Citations=3).

7) Genetically driven CD39 expression shapes human tumor-infiltrating CD8+ T-cell functions.
Gallerano D, Ciminati S, Grimaldi A, Piconese S, Cammarata I, Focaccetti C, Pacella I, Accapezzato D, Lancellotti F, Sacco L, Caronna R, **Melaiu O**, Fruci D, D'Oria V, Manzi E, Sagnotta A, Parrino C, Coletta D, Peruzzi G, Terenzi V, Battisti A, Cassoni A, Fadda MT, Brozzetti S, Fazzi K, Grazi GL, Valentini V, Chirletti P, Polimeni A, Barnaba V, Timperi E.
Int J Cancer. 2020 Nov 1;147(9):2597-2610. PMID: 32483858 (IF 5.145).

8) Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors.
Melaiu O, Lucarini V, Cifaldi L, Fruci D.
Front Immunol. 2020 Jan 21;10:3038. PMID: 32038612 (IF 5.085; Citations=26).

9) ERAP1 promotes Hedgehog-dependent tumorigenesis by controlling USP47-mediated degradation of βTrCP.
Bufalieri F, Infante P, Bernardi F, Caimano M, Romania P, Moretti M, Severini L, Talbot J, **Melaiu O**, Tanori M, Di Magno L, Bellavia D, Puget S, De Smaele E, Canettieri G, Guardavaccaro D, Busino L, Peschiaroli A, Pazzaglia S, Giannini G, Melino G, Locatelli F, Gulino A, Ayrault O, Doriana Fruci D, Di Marcotullio L.
Nat Commun. 2019 Jul 24;10(1):3304. PMID: 31341163 (IF 12.121; Citations=11).

10) Counter-regulation of regulatory T cells by autoreactive CD8+ T cells in rheumatoid arthritis.
Cammarata I, Martirea C, Citroa A, Raimondo D, Fruci D, **Melaiu O**, D'Oria V, Carone C, Peruzzi G, Cerboni C, Santoni A, JSidney J, Sette A, Paroli M, Caccavale R, Milanetti E, Riminucci M, Timperi E, Piconese S, Manzo A, Montecucco C, Scrivo R, Valesini G, Cariani E, Barnaba V.
J Autoimmun. 2019 May;99:81-97. PMID: 30777378 (IF 7.641; Citations=9).

11) Tumor-infiltrating T cells and PD-L1 expression in childhood malignant extracranial germ-cell tumors.
Melaiu O*, Boldrini R*, De Pasquale MD*, Chierici M, Jurman G, Benedetti MC, Salfi NC, Castellano A, Collini P, Furlanello C, Pistoia V, Cifaldi L, Terenziani M, Fruci D. *=Equally contribution
Oncoimmunology. 2018 Dec 13;8(2):e1542245. PMID: 30713803 (IF 5.869; Citations=3).

12) Identification of a Genetic Variation in ERAP1 Aminopeptidase that Prevents Human Cytomegalovirus miR-UL112-5p-Mediated Immunoevasion.

Romania P, Cifaldi L, Pignoloni B, Starc N, D'Alicandro V, **Melaiu O**, Li Pira G, Giorda E, Carrozzo R, Bergvall M, Bergström T, Alfredsson L, Olsson T, Kockum I, Seppälä I, Lehtimäki T, Hurme MA, Hengel H, Santoni A, Cerboni C, Locatelli F, D'Amato M, Fruci D.
Cell Rep. 2017 Jul 25;20(4):846-853. PMID: 28746870 (IF 8.109; Citations=11).

13) MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma.
Brandetti E, Veneziani I, **Melaiu O**, Pezzolo A, Castellano A, Boldrini R, Ferretti E, Fruci D, Moretta L, Pistoia V, Locatelli F, Cifaldi L.
Oncoimmunology. 2017 Apr 20;6(6):e1316439. PMID: 28680748 (IF 5.869; Citations=15).

14) Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism.
Melaiu O*, De Santi C*, Bonotti A, Cascione L, Di Leva G, Foddis R, Cristaudo A, Lucchi M, Mora M, Truini A, Tironi A, Murer B, Boldorini R, Cipollini M, Gemignani F, Gasparini P, Mutti L, Landi S.
*Equally contribution.
Sci Rep. 2017 Jun 9;7(1):3140. PMID: 28600498. (IF 3.998; Citations=29).

15) Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines.
Melaiu O, Catalano C, De Santi C, Cipollini M, Figlioli G, Pellè L, Barone E, Evangelista M, Guazzelli A, Boldrini L, Sensi E, Bonotti A, Foddis R, Cristaudo A, Mutti L, Fontanini G, Gemignani F, Landi S.
Genes Cancer. 2017 Jan;8(1-2):438-452. PMID: 28435517 (IF 2.43; Citations=9).

16) PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma.
Melaiu O, Mina M, Chierici M, Boldrini R, Jurman G, Romania P, D'Alicandro V, Benedetti MC, Castellano A, Liu T, Furlanello C, Locatelli F, Fruci D.
Clin Cancer Res. 2017 Aug 1;23(15):4462-4472. PMID: 28270499 (IF 10.107; Citations=41).

17) Expression status of candidate genes in mesothelioma tissues and cell lines.
Melaiu O, Melissari E, Mutti L, Bracci E, De Santi C, Iofrida C, Di Russo M, Cristaudo A, Bonotti A, Cipollini M, Garritano SI, Foddis R, Lucchi M, Pellegrini S, Gemignani F, Landi S.
Mutat Res. 2015 Jan;771:6-12. PMID: 25771974 (IF 5.803; Citations=17)

18) A common polymorphism within MSLN affects miR-611 binding site and soluble mesothelin levels in healthy people.
Garritano S, De Santi C, Silvestri R, **Melaiu O**, Cipollini M, Barone E, Lucchi M, Barale R, Mutti L, Gemignani F, Bonotti A, Foddis R, Cristaudo A, Landi S.
J Thorac Oncol. 2014. 9(11):1662-8. (IF 13.357; Citations=11)

19) MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma.
Melaiu O, Stebbing J, Lombardo Y, Bracci E, Uehara N, Bonotti A, Cristaudo A, Foddis R, Mutti L, Barale R, Gemignani F, Giamas G, Landi S.
PLoS One. 2014 Jan 21;9(1):e85935. PMID: 24465798 (IF 2.776; Citations=13)

20) The regulatory roles of phosphatases in cancer.
Stebbing J, Lit LC, Zhang H, Darrington RS, **Melaiu O**, Rudraraju B, Giamas G.
Oncogene. 2014 Feb 20;33(8):939-53. PMID: 23503460. (IF 7.971; Citations=53)

Dichiarazione sostitutiva di certificazioni/dell'atto di notorietà
(Artt. 46 e 47 del D.P.R. 28 dicembre 2000, n. 445)

La sottoscritta Melaiu Ombretta a conoscenza di quanto prescritto dall'art. 76 del D.P.R. 28 dicembre 2000 n. 445, sulla responsabilità penale cui può andare incontro in caso di falsità in atti e di dichiarazioni mendaci, nonché di quanto prescritto dall'art. 75 del D.P.R. 28 dicembre 2000 n. 445, sulla decadenza dai benefici eventualmente conseguenti al provvedimento emanato sulla base di dichiarazioni non veritiere, ai sensi e per gli effetti del citato D.P.R. n. 445/2000 e sotto la propria personale responsabilità:

DICHIARA

che tutte le informazioni contenute nel proprio curriculum vitae sono veritiere.

Roma, 10/03/2021

Ombretta Melaiu